(Q53324924)

13 May 2018

title

Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. (English)

1 reference

13 May 2018

author name string

Hwi Young Kim

1

1 reference

13 May 2018

Joong-Won Park

2

1 reference

13 May 2018

Jungnam Joo

3

1 reference

13 May 2018

Hyoseok Kim

4

1 reference

13 May 2018

Sang Myung Woo

5

1 reference

13 May 2018

Woo Jin Lee

6

1 reference

13 May 2018

Chang-Min Kim

7

1 reference

13 May 2018

publication date

1 November 2013

1 reference

13 May 2018

Journal of Gastroenterology and Hepatology

published in

1 reference

13 May 2018

volume

28

1 reference

13 May 2018

issue

11

1 reference

13 May 2018

page(s)

1756-1761

1 reference

13 May 2018

cites work

Cancer statistics, 2008

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.

21 January 2018

1 reference

[Practice guidelines for management of hepatocellular carcinoma 2009].

21 January 2018

1 reference

Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.

21 January 2018

1 reference

Current strategy for staging and treatment: the BCLC update and future prospects.

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study

21 January 2018

1 reference

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

21 January 2018

1 reference

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

21 January 2018

1 reference

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.

21 January 2018

1 reference

Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function

21 January 2018

1 reference

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits

21 January 2018

1 reference

Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area

21 January 2018

1 reference

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

21 January 2018

1 reference

Management of cirrhosis and ascites

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JGH.12310

1 reference

13 May 2018

1 reference

13 May 2018